TITLE

Drug-resistant TB: Should Americans be worried?

AUTHOR(S)
Magill-Lewis, Jillene
PUB. DATE
July 2007
SOURCE
Drug Topics;7/9/2007, Vol. 151 Issue 13, p17
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the emergence of drugs that offer the potential to be effective against extensively drug-resistant tuberculosis (XDR-TB) in the U.S. XDR-TB is resistant to capreomycin, amikacin, kanamycin, and fluoroquinolones. The OPC-67683 and PA-824 are part of a class of antibiotics called nitroimidazoles under clinical trials. Diarylquinolines are a class of antimycobacterials that performed well in pre-clinical and Phase I trials. Moxifloxacin from Bayer and Avelox is scheduled for Phase III trials for XDR-TB.
ACCESSION #
25886317

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics